Generic drug: sulfur hexafluoride lipid-type A microspheres
Brand name: Lumason
What is Lumason (sulfur hexafluoride lipid-type A microspheres), and how does it work?
Lumason (sulfur hexafluoride lipid–type A microspheres) is an ultrasound contrast agent indicated for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms, and in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
What are the side effects of Lumason?
WARNING
SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred
uncommonly during or following the injection of ultrasound contrast agents,
including sulfur hexafluoride lipid microspheres. Most serious reactions occur
within 30 minutes of administration.
Assess all patients for the presence
of any condition that precludes administration.
- Always have
resuscitation equipment and trained personnel readily available.
Common side effects of Lumason include:
- headache
- nausea
- changes in taste
- injection site pain or warmth
- feeling hot
- chest discomfort or pain,
- or dizziness
What is the dosage for Lumason?
Important Administration Instructions
Do not administer Lumason by
intra-arterial injection.
Recommended Dosage
Echocardiography
Adults
- The recommended dose of Lumason after reconstitution is 2 mL administered as an intravenous bolus injection during echocardiography.
- During a single examination, a second injection of 2 mL may be administered to prolong contrast enhancement.
- Follow each Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
Pediatric Patients
- The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during echocardiography.
- During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
- Do not exceed 2 mL per injection. Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
Ultrasonography Of The Liver
Adults
- The recommended dose of Lumason after reconstitution in adult patients is 2.4 mL administered as an intravenous injection during ultrasonography of the liver.
- During a single examination, a second injection of 2.4 mL may be administered, if needed.
- Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection, USP.
Pediatric Patients
- The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered as an intravenous injection during ultrasonography of the liver.
- During a single examination, a second injection of 0.03 mL per kg may be administered, if needed.
- Do not exceed 2.4 mL per injection.
- Follow Lumason injection with an intravenous flush of 0.9% Sodium Chloride Injection, USP.
Ultrasonography Of The Urinary Tract
Pediatric Patients
- The recommended dose of Lumason after reconstitution is 1 mL.
- The bladder may be refilled with 0.9% Sodium Chloride Injection, USP for a second cycle of voiding and imaging, without the need of a second Lumason administration.
What drugs interact with Lumason?
No information provided
Is Lumason safe to use while pregnant or breastfeeding?
- There are no data with Lumason use in pregnant women to inform any drug-associated risks.
- There are no data on the presence of Lumason in human milk, the effects on the breastfed infant, or the effects on milk production.
- The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Lumason and any potential adverse effects on the breastfed infant from Lumason or from the underlying maternal condition.